An observational study in Attention-Deficit/ Hyperactivity Disorder (ADHD), sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 6 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Calgary · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Canada.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2024, is one of 13 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 76th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →12 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada are open now. Recruiting first, the newest first:
Dar Clinical Research Inc. · Sites in Canada
Ages 65+
University of Calgary · Sites in Canada
Ages 9–15
University of Calgary · Sites in Canada
Ages 10+ · Women only · Healthy volunteers
Holland Bloorview Kids Rehabilitation Hospital · Sites in Canada
Ages 8–17
Douglas Mental Health University Institute · Sites in Canada
Ages 9–25 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 18 · Phase 4 17
First in 1999; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 133 across 331 observational studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 108 across the 72 interventional studies, 195 across the 13 observational. Of the 57 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 85 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 4 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
6 of the studies in Attention Deficit Disorder with Hyperactivity with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07597707University of CalgaryInvestigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan | 2026-12-31 |
| NCT05916339Daniel CouryAWARE: Management of ADHD in Autism Spectrum Disorder | 2027-01-01 |
| NCT07926776University of ManitobaSupporting Families of School-Aged Children With ADHD: A Dual-Generation Therapy Approach Through the BRIDGE Program | 2027-05-31 |
| NCT07710014Dar Clinical Research Inc.Evaluation of Foquest in Adults 65 Years and Older With ADHD | 2027-07-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Background: ADHD is a common neurodevelopmental disorder affecting children and adolescents, with psychostimulants, specifically slow-release methylphenidate (e.g., Biphentin®, Concerta®), being a first-line treatment option. However, the response to medications varies significantly among individuals, with some experiencing limited benefits or intolerable side effects. Unlike other areas of psychiatry, ADHD pharmacotherapy lacks genetic markers to guide treatment decisions, resulting in delayed symptom relief and diminished quality of life for patients.
Objectives:
The criteria were revised on the registry on Oct 29, 2026. See what changed
Children and adolescent with primary diagnosis of ADHD (all types), aged 6-24 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients will be eligible for participation if all the following are true.
Exclusion Criteria:
Patients will be excluded from participation if any of the following are true.
Change in ADHD symptom severity
Strengths and Weaknesses of Attention-Deficit/Hyperactivity Symptoms and Normal Behavior Scale (SWAN) Rating Scale for ADHD. Score range = -90 to +90, with higher scores indicative of worse outcome.
Time frame: Baseline and 1, 2, 3, and 4 weeks post-baseline
Side effect frequency and severity
CADDRA ADHD Medication and Side Effect Form
Time frame: 1, 2, 3, and 4 weeks post-baseline
Methylphenidate/ritalinic acid exposure
Methylphenidate and ritalinic acid trough plasma levels
Time frame: 4 weeks post-baseline
Change in working memory
Sorting Working Memory Test (7 minutes; administered orally and online with research team member). An assessment of working memory. A participant is asked to recall and sequence different stimuli that are presented visually and via audio. Higher scores indicate better outcome.
Time frame: Baseline and 4 weeks post-baseline
Change in attention
Dimension Change Card Sort Test (8 minutes; administered online). An assessment of cognitive flexibility and attention. A participant is asked to match a series of picture pairs to a target picture. Higher scores indicate better outcome.
Time frame: Baseline and 4 weeks post-baseline
Change in inhibitory control
Flanker Inhibitory Control and Attention Test (7 minutes; administered online). An assessment of inhibitory control and attention. A participant is asked to focus on a particular stimulus while inhibiting attention to the stimuli flanking it. Higher scores indicate better outcome.
Time frame: Baseline and 4 weeks post-baseline
Change in impulse control
Stop Signal Task (10 minutes; administered online). An assessment of impulse control. A participant is presented with a target stimulus and are asked to respond to the stimulus as fast as possible. Higher score indicate better outcome.
Time frame: Baseline and 4 weeks post-baseline
Change in functioning
Columbia Impairment Scale. Score range 0-52, with higher scores indicative of worse outcome.
Time frame: Baseline and 4 weeks post-baseline
Change in child quality of life
Pediatric Quality of Life Inventory (PedsQoL). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better quality of life.
Time frame: Baseline and 4 weeks post-baseline
Change in carer quality of life
Care-related Quality of Life instrument (Carer QoL-7D). Utility tariffs for the CarerQol have been developed to calculate a CarerQol-7D utility score from the responses on the seven dimensions, ranging between 0 ('worst imaginable caregiving situation') and 100 ('best imaginable caregiving situation'). Higher utility scores thus reflect better care-related quality of life.
Time frame: Baseline and 4 weeks post-baseline
Plan to share: Yes — Anonymized, individual participant PGx-STaR data will be shared using a controlled-access model. Under this model, the data will be released to a researcher if access criteria are met. All requests for data sharing should be made to the Co-Principal Investigators who will be responsible for reviewing and granting requests. Requestors should provide a research proposal for review. In the event that a data sharing request is declined, reasons will be provided to the requestor. If the data sharing request is granted, a data-sharing agreement will be initiated by the Co-Principal Investigators alongside the University of Calgary (lead institution). This agreement will include information on the individual data to be shared; if other documents will be available (e.g., statistical codes, data dictionary), when the data will be available and for how long, and how data access will be provided (e.g., file transfer).
Access criteria: The requestor is affiliated with an academic institution as an independent investigator or trainee of an independent investigator; The proposed research question(s) and hypothesis(es) are specific, measurable, and achievable; The proposed research project will be governed/overseen by a local legal/regulatory body; The proposed research project poses no risk of invasion of privacy or breaches of confidentiality for trial participants; A member of the proposed research team has sufficient statistical skills to carry out the proposed analytic plan; The requestor has sufficient financial and/or human resources to see the proposed research project to completion; The proposed research question(s) and hypothesis(es) do not conflict with active or planned studies of the Co-Principal Investigators.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Aug 2028, 52 months after the start.
Of 86 non-industry observational studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 52 months is above that.
Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →